Synedica BPC 157 & TB 500

What BPC-157 and TB-500 Are

BPC-157 ("Body Protection Compound-157") is a synthetic 15-amino-acid peptide, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from a partial sequence identified in human gastric juice. It carries CAS number 137525-51-0, molecular formula C62H98N16O22, and a molecular weight of approximately 1,419.5 g/mol. Preclinical research has examined it for cytoprotective, angiogenic and anti-inflammatory activity in tissue-repair models.

TB-500 is a synthetic heptapeptide — Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, written Ac-LKKTETQ — corresponding to the N-acetylated active fragment at residues 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-binding protein. TB-500 is not the full Tβ4 protein; it is a much smaller synthetic fragment engineered to isolate the region associated with actin sequestration and cell migration. It carries CAS number 885340-08-9, molecular formula C38H68N10O14, and a molecular weight of approximately 889.0 g/mol. The two peptides are chemically and structurally distinct — a gastric-derived 15-mer and a thymosin-derived 7-mer fragment — studied together because both are examined in overlapping tissue-repair and regeneration research.

What Current Research Says

A 2025 systematic review in HSS Journal by Vasireddi and colleagues examined 36 studies on BPC-157 published between 1993 and 2024 (35 preclinical, one clinical). It reported that BPC-157 "enhances growth hormone receptor expression and several pathways involved in cell growth and angiogenesis, while reducing inflammatory cytokines" in preclinical models, that the compound is "metabolized in the liver, with a half-life of less than 30 minutes," and that preclinical toxicity testing found no adverse effects across tested doses. The single identified human study — 12 patients receiving intra-articular knee injections for chronic pain, not a Synedica UK product — reported that 7 of 12 patients had relief lasting over 6 months, but the review's authors stated plainly that "no clinical safety data were found" and that "clinical safety in humans remains unknown" (Vasireddi et al., 2025, HSS J).

A separate 2025 pilot study published in Alternative Therapies in Health and Medicine examined intravenous BPC-157 infusion in humans and reported it "was tolerated with no reported side effects" (Lee & Burgess, 2025, Altern Ther Health Med), though this remains a small early-phase safety pilot, not an efficacy trial.

For TB-500, a 2026 scoping review in Applied Sciences by McGuire and colleagues screened 1,772 records down to 80 included studies on thymosin beta-4 and TB-500 in tissue healing. It found the evidence base "skews toward preclinical work," that most studies examined native Tβ4 rather than the TB-500 fragment specifically, with "direct TB-500 evidence limited to a single included study," and that there were "no human interventional studies of administered TB4 or TB-500" for tendon, ligament, muscle, bone or cartilage applications (McGuire et al., 2026, Appl Sci). None of these findings constitute a treatment claim for this research-use product; they describe what has been studied in registered trials, pilot safety studies and preclinical literature on the two molecules, not what a laboratory-use compound sold by Synedica UK does for an individual.

Specifications

Purity, Batch Testing and Certificate of Analysis Standards

Every Synedica BPC-157 & TB-500 Blend offered for sale is supplied with third-party analytical documentation rather than a single purity percentage repeated across listings. A Certificate of Analysis (COA) should show the specific batch or lot number, the analytical method used (typically HPLC or mass spectrometry), the measured purity result for that batch, and the issuing laboratory. Given how many UK listings for this blend quote a purity figure without offering batch-specific evidence, and how often "TB-500" is described inaccurately as the full thymosin beta-4 protein rather than the smaller synthetic fragment, researchers should treat vague chemical descriptions and COA-on-request-only listings as a red flag rather than an oversight. See our contact page to request a Certificate of Analysis for a specific batch.

Sourcing and Verification

Buying a high-demand blend like BPC-157 and TB-500 from a UK-based supplier does not remove the need to verify what arrives. Before ordering, check that the listing states research-use status clearly, that batch documentation is offered rather than promised only "on request," and that each compound's identity (CAS number, molecular formula) is independently verifiable against a source such as PubChem. The Synedica BPC-157 & TB-500 Blend is offered for sale on this basis, with documentation available per batch. The full catalogue is browsable on the research products page.